Green Cross·SK Plasma... K-Blood Products Aiming to Enter Indonesia

Green Cross Establishes Plan for Blood Product Plant Construction
SK Plasma Also to Export 1 Million Liter Scale Plant

News of domestic companies producing blood products entering the Indonesian market continues.

GC Green Cross has signed a plasma supply business agreement for blood product contract manufacturing and plant business with the Indonesian Red Cross and pharmaceutical company Triman. James Triman, CEO of Triman Pharmaceutical; Yusuf Kala, President of the Indonesian Red Cross; and Yoon Young-jun, Head of Global Business Unit at GC Green Cross (from left).
[Photo by GC Green Cross]

On the 14th, GC Green Cross announced on the 15th that it had signed a plasma supply business agreement for blood product contract manufacturing and plant projects with the Indonesian Red Cross and local pharmaceutical company Triman (P.T Triman). Following the final approval of the related business license from the Indonesian Ministry of Health and Welfare on the 1st, this tripartite business agreement is said to have secured a stable supply of raw plasma from the Indonesian Red Cross, laying the groundwork for global plant construction and technology transfer.

Blood products are medicines derived from blood, manufactured by fractionating and purifying components within the blood into pharmaceutical forms such as albumin and immunoglobulin. They are essential treatments used in various fields including shock due to excessive bleeding, congenital immunodeficiency diseases, and hemophilia.

GC Green Cross holds expertise in constructing blood product plants in various countries such as China and Canada, following its export of a blood product plant to Thailand as the first domestic pharmaceutical company. Since the 1970s, starting with albumin, it has produced various blood products, and in 2009, it completed the Ochang plant, the largest blood product factory in Asia, currently exporting 12 items to 32 countries.

The Indonesian government is promoting a plan to realize stable domestic production of blood products using plasma from Indonesian citizens through the construction of blood product plants and technology transfer projects, which currently rely entirely on imports. The Indonesian blood product market is worth 1.15 trillion Indonesian Rupiah (approximately 98.4 billion KRW), which is not a large market. However, the annual growth rate is approaching 11%, and demand is expected to continue increasing after self-sufficiency in blood products is achieved.

A GC Green Cross official said, "This business agreement was achieved as the Indonesian public and private sectors recognized the high level of technology GC Green Cross has held in the blood product field for half a century," adding, "We will do our best to contribute to improving the health of the Indonesian people in the future."

Perspective view of the blood product factory that SK Plasma will build in Indonesia.
Photo by SK Plasma

Meanwhile, SK Plasma, a subsidiary of SK Discovery, is also exporting a blood product plant to Indonesia in partnership with Daewoong Infion, a local joint venture of Daewoong Pharmaceutical. Construction began last month, with completion targeted for 2025. The facility will be capable of processing 1 million liters of raw plasma annually.

This content was produced with the assistance of AI translation services.